7 completed, 1 terminated. 8 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 8 | Completed 7, Terminated 1 |
Follow Excessive Daytime Sleepiness: new trials by email Literature Review of Excessive Daytime Sleepiness trials Research Report on Excessive Daytime Sleepiness
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Four-week Study of the Safety and Efficacy of NLS-2 (Mazindol Extended Release) in the Treatment of Narcolepsy mazindol extended release, Placebo - Narcolepsy, Excessive Daytime Sleepiness | Phase 2 | Completed | NLS Pharmaceutics | 67 | 2021-09-13 | 2022-08-12 |
| Safety and Efficacy of Pitolisant on Excessive Daytime Sleepiness and Other Non-Muscular Symptoms in Patients With Myotonic Dystrophy Type 1 Pitolisant Oral Tablet, Placebo oral tablet - Myotonic Dystrophy 1, Excessive Daytime Sleepiness | Phase 2 | Completed | Harmony Biosciences Management, Inc. | 30 | 2021-06-28 | 2026-09-04 |
| BEN-2001 in Parkinson Disease Patients With Excessive Daytime Sleepiness BEN-2001, Placebo - Excessive Daytime Sleepiness, Parkinson Disease | Phase 2 | Completed | BenevolentAI Bio | 244 | 2017-11-10 | 2025-03-10 |
| Dose-range Finding Study of BF2.649 Effect on Patients With Obstructive Sleep Apnea (OSA) BF2.649, Placebo - Obstructive Sleep Apnoea, Excessive Daytime Sleepiness | Phase 2 | Completed | Bioprojet | 110 | 2010-10-01 | 2012-06-15 |
| A Study Of A Novel Compound For Excessive Daytime Sleepiness Associated With Narcolepsy Placebo, PF-03654746 - Excessive Daytime Sleepiness, Narcolepsy | Phase 2 | Completed | Pfizer | 95 | 2009-11-01 | 2014-05-09 |
| Treatment of Refractory Excessive Daytime Sleepiness in Patients With Obstructive Sleep Apnea/Hypopnea Syndrome (OSA/HS) Using Nasal Continuous Positive Airway Pressure (nCPAP) Therapy (0249-015) Comparator: MK0249, Comparator: placebo, Comparator: modafinil - Sleep Apnea, Obstructive, Hypopnea Syndrome | Phase 2 | Terminated | Merck Sharp & Dohme LLC | 125 | 2008-02-01 | 2015-05-13 |
| Dose Range Finding Study of BF2.649 Versus Placebo to Treat Excessive Daytime Sleepiness in Parkinson's Disease Patients Placebo, BF 2.649 5 mg, BF 2.649 10 mg - Excessive Daytime Sleepiness, Parkinson's Disease | Phase 2 | Completed | Bioprojet | 108 | 2007-10-01 | 2012-06-11 |
| Sedating Antidepressant Improves Driving Safety in Patients With Major Depressive Disorder Driving Simulator Testing, Mirtazapine Treatment - Depression, Excessive Daytime Sleepiness | Phase 2 | Completed | University Health Network, Toronto | 16 | 2003-04-01 | 2006-10-09 |
Disorders of Excessive Somnolence (8) · Narcolepsy (2) · Parkinson Disease (2) · Sleep Apnea, Obstructive (2) · Depression (1) · Depressive Disorder, Major (1) · Myotonic Dystrophy (1) · Sleep Wake Disorders (1)
Dyssomnias (8) · Mental Disorders (8) · Nervous System Diseases (8) · Sleep Disorders, Intrinsic (8) · Sleep Wake Disorders (7) · Neurodegenerative Diseases (3) · Apnea (2) · Basal Ganglia Diseases (2) · Brain Diseases (2) · Central Nervous System Diseases (2) · Movement Disorders (2) · Parkinsonian Disorders (2) · Respiration Disorders (2) · Respiratory Tract Diseases (2) · Sleep Apnea Syndromes (2)
pitolisant (3) · N-ethyl-3-fluoro-3-(3-fluoro-4-(pyrrolidinylmethyl)phenyl)cyclobutanecarboxamide (1) · bavisant (1)
Bioprojet (2) · BenevolentAI Bio (1) · Harmony Biosciences Management, Inc. (1) · Merck Sharp & Dohme LLC (1) · NLS Pharmaceutics (1) · Pfizer (1) · University Health Network, Toronto (1)
United States (4) · Canada (2) · France (2)
Carlos Camozzi, MD (1) · Carsten Moeller (1) · Colin M. Shapiro, MBBCh, PhD (1) · Evelyne De Paillette, MD (1) · Sharon A. Chung, PhD (1) · William G Ondo, M.D (1)